<Record>
<Term>Lyso-Thermosensitive Liposome Doxorubicin</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Doxorubicin Preparation</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Enzyme Inhibitor/Topoisomerase Inhibitor/Topoisomerase-II Inhibitor/Anthracycline Antineoplastic Antibiotic/Doxorubicin Preparation/Lyso-Thermosensitive Liposome Doxorubicin</ClassificationPath>
<BroaderTerm>Topoisomerase Inhibitor</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Enzyme Inhibitor</BroaderTerm>
<BroaderTerm>Lyso-Thermosensitive Liposome Doxorubicin</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Topoisomerase-II Inhibitor</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<BroaderTerm>Doxorubicin Preparation</BroaderTerm>
<BroaderTerm>Anthracycline Antineoplastic Antibiotic</BroaderTerm>
<Synonym>Heat-Activated Liposomal Doxorubicin Hydrochloride</Synonym>
<Synonym>Lyso-Thermosensitive Liposome Doxorubicin</Synonym>
<Synonym>Temperature Sensitive Liposome Encapsulated Doxorubicin</Synonym>
<Synonym>ThermoDox</Synonym>
<Description>A temperature-sensitive liposomal formulation of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Upon intravenous administration, circulating thermosensitive liposomes are activated locally by increasing the tumor temperature to 40-41 degrees Celsius using an external heat source. The elevated temperature causes compositional changes in the liposomes, creating openings that allow for the release of encapsulated doxorubicin. Compared to non-thermosensitive liposomes, lyso-thermosensitive liposomes deliver higher concentrations of a cytotoxic agent to a heat-treated tumor site while sparing normal tissues unexposed to heat treatment.</Description>
<Source>NCI Thesaurus</Source>
</Record>
